Replication Data for: Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function. Lauren De Bruyn et al. Crit Care 2024.

Data integrated in the manuscript “Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function”. Hypocholesterolemia hallmarks critical illness though the underlying pathophysiology is incompletely understood. As low circulating cholesterol levels could partly be due to an increased conversion to cortisol/corticosterone, we hypothesized that glucocorticoid treatment, via reduced de novo adrenal cortisol/corticosterone synthesis, might improve cholesterol availability and as such affect adrenal gland and skeletal muscle function. In a matched set of prolonged critically ill patients (n = 324) included in the EPaNIC RCT, a secondary analysis was performed to assess the association between glucocorticoid treatment and plasma cholesterol from ICU admission to day five. Next, in a mouse model of cecal ligation and puncture-induced sepsis, septic mice were randomized to receive either hydrocortisone (1.2 mg/day) (n = 17) or placebo (n = 15) for 5 days, as compared with healthy mice (n = 18). Plasma corticosterone, cholesterol, and adrenocortical and myofiber cholesterol were quantified. Adrenal structure and steroidogenic capacity were evaluated. Muscle force and markers of atrophy, fibrosis and regeneration were quantified. In a consecutive mouse study with identical design (n = 24), whole body composition was assessed by EchoMRI to investigate impact on lean mass, fat mass, total and free water. Methodology of data collection and processing is described in the method section of the manuscript DOI:10.1186/s13054-024-05079-8

Jaar van publicatie:2024

Toegankelijkheid:restricted

Uitgever:KU Leuven RDR

Licentie:Other

Formaat:csv, txt

Trefwoorden: adrenal insufficiency, aldosterone, cholesterol, glucocorticoids, muscle weakness, sepsis